We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outlook of the jakinibs in systemic lupus erythematous after baricitinib failed.
- Authors
Mok, Chi Chiu
- Abstract
This article discusses the use of jakinibs, small molecules that selectively block the actions of Janus kinase (JAK) proteins, in the treatment of systemic lupus erythematosus (SLE). SLE is a complex autoimmune disease characterized by abnormal expression of certain cytokines and activation of immune cells. The article specifically focuses on the efficacy and safety of baricitinib, a JAK1/2 inhibitor, in SLE. While some studies have shown positive results, others have been inconclusive, and there are concerns about serious adverse events associated with baricitinib. The article also mentions other targeted small molecules that have shown promising results in SLE. Overall, more research is needed to determine the effectiveness of jakinibs in treating SLE.
- Subjects
LUPUS nephritis; AUTOIMMUNE diseases; BARICITINIB; BRUTON tyrosine kinase; SYSTEMIC lupus erythematosus; TALL-1 (Protein)
- Publication
International Journal of Rheumatic Diseases, 2024, Vol 27, Issue 2, p1
- ISSN
1756-1841
- Publication type
Article
- DOI
10.1111/1756-185X.15082